Quantum BioPharma Launches $7 Million Whistleblower Program Targeting Stock Manipulation

Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) has implemented a public whistleblower policy offering cash rewards of up to USD $7 million for verifiable evidence of stock manipulation involving the Company's shares. The biopharmaceutical company, which focuses on developing treatments for neurodegenerative, metabolic, and alcohol misuse disorders, will pay the reward from the net proceeds of its ongoing lawsuit. Eligible participants can submit information directly to reward@quantumbiopharma.com or by calling 1-833-571-1811.

The reward will be granted if the submitted information materially contributes to a final, non-appealable judgment or binding settlement in Quantum BioPharma's favor. This initiative was approved by the company's board and audit committee with input from multiple law firms. The program underscores Quantum's commitment to transparency, accountability, and market integrity while encouraging simultaneous reporting to the U.S. SEC and Canadian regulatory authorities. The company's latest news and updates relating to QNTM are available in the company's newsroom at https://ibn.fm/QNTM.

Quantum BioPharma maintains a diverse portfolio of innovative assets and biotech solutions. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., the company is focused on the research and development of its lead compound, Lucid-MS. This patented new chemical entity has been shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. The company's drug candidates are in different stages of development for challenging neurodegenerative and metabolic disorders.

The company also invented unbuzzd(TM) and spun out its OTC version to Unbuzzd Wellness Inc., led by industry veterans. Quantum BioPharma retains ownership of 20.11% of Unbuzzd Wellness Inc. as of March 31, 2025. The agreement with Unbuzzd Wellness Inc. includes royalty payments of 7% of sales from unbuzzd(TM) until payments to Quantum BioPharma total $250 million, after which the royalty drops to 3% in perpetuity. Quantum BioPharma retains 100% of the rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses.

This whistleblower program represents a significant step in corporate governance and market protection. By offering substantial financial incentives for reporting stock manipulation, Quantum BioPharma aims to deter illegal trading practices that can harm shareholder value and market confidence. The program's structure, which requires information to materially contribute to legal outcomes, ensures that rewards are tied to meaningful results rather than unsubstantiated claims. For more information about the specialized communications platform that distributed this announcement, visit https://www.InvestorWire.com.

The implementation of such a substantial reward program highlights the growing concern about market manipulation in the biopharmaceutical sector, where stock volatility can significantly impact companies' ability to fund research and development. Quantum BioPharma's approach demonstrates how companies can take proactive measures to protect their shareholders and maintain market integrity while pursuing legal remedies against potential manipulative activities affecting their stock performance.